Coexistence of Autoimmune Encephalitis and Other Systemic Autoimmune Diseases
نویسندگان
چکیده
منابع مشابه
Systemic Autoimmune Diseases 2014
1Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China 2Laboratory of Autoimmunity, School of Biological Sciences, University of Texas at El Paso, El Paso, TX 79968, USA 3Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198-7660, USA 4Department of Rheumatology, Peking Un...
متن کاملSystemic Autoimmune Diseases
1 Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China 2Department of Biological Sciences, University of Texas at El Paso, 500 West University Avenue, El Paso, TX 79968, USA 3Microbiology, College of Medicine University of Nebraska Medical Center, Omaha, NE 68198-7660, USA 4Department of Rheumatology, Peking Union Medical College Hosp...
متن کاملO 16: Challenge in Diagnosis and Management of Autoimmune Encephalitis
The first description of an autoimmune encephalitis dates back to 1888, when Hermann Oppenheim described a patient with neurological symptoms but no underlying brain pathology. The field of autoimmune encephalitides associated with antibodies targeting cell-surface antigens is rapidly expanding and new antibodies are discovered frequently. Autoimmune encephalitis is a difficult clinical diagnos...
متن کاملO 19: Treatment and Porognosis of Autoimmune Encephalitis
AE is a serious medical condition in which the immune system attacks the brain, impairing function. With rapid diagnosis and appropriate treatment, many patients recover most or all functions. However, not all patients experience full recovery; with approximately 6% mortality and other patients who never regain significant brain and/or bodily functions. Autoimmune encephalitis can pro...
متن کاملBiomarkers in Systemic Autoimmune Diseases
In an ideal scenario, a biomarker would both reveal the driver of disease and identify an effective treatment. In oncology, genetic biomarkers that molecularly or clinically classify patient populations for targeted therapies, e.g., BRAF [1] and HER-2 [2], have been clinically validated and are reaching this ideal. However, biomarkers are necessarily based on the pathobiology of the underlying ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Neurology
سال: 2019
ISSN: 1664-2295
DOI: 10.3389/fneur.2019.01142